The gonadal steroids estrogen and progesterone have been shown to have neuroprotective properties against various neurodegenerative conditions. Excessive concentrations of glutamate have been found to exert neurotoxic properties. We hypothesize that estrogen and progesterone provide neuroprotection by the autoregulation of blood and brain glutamate levels. Venous blood samples (10 ml) were taken from 31 men and 45 women to determine blood glutamate, estrogen, progesterone, glucose, glutamate-pyruvate transaminase (GPT), and glutamate-oxaloacetate transaminase (GOT) levels, collected on Days 1, 7, 12, and 21 of the female participants' menstrual cycle. Blood glutamate concentrations were higher in men than in women at the start of menstruation (P , 0.05). Blood glutamate levels in women decreased significantly on Days 7 (P , 0.01), 12 (P , 0.001), and 21 (P , 0.001) in comparison with blood glutamate levels on Day 1. There was a significant decrease in blood glutamate levels on Days 12 (P , 0.001) and 21 (P , 0.001) in comparison with blood glutamate levels on Day 7. Furthermore, there was an increase in blood glutamate levels on Day 21 compared with Day 12 (P , 0.05). In women, there were elevated levels of estrogen on Days 7 (P , 0.05), 12, and 21 (P , 0.001), and elevated levels of progesterone on Days 12 and 21 (P , 0.001). There were no differences between men and women with respect to blood glucose concentrations. Concentrations of GOT (P , 0.05) and GPT (P , 0.001) were significantly higher in men than in women during the entire cycle. The results of this study demonstrate that blood glutamate levels are inversely correlated to levels of plasma estrogen and progesterone.
INTRODUCTION
The gonadal steroids estrogen and progesterone are known female sex hormones associated with several reproductive functions. There is substantial biologic evidence to support that estrogen and progesterone also play an important role in the development, growth, differentiation, maturation, and function of various tissues throughout the body, including the peripheral and central nervous system [1] .
Estrogen and progesterone have significant neuroprotective properties against various neurodegenerative conditions [2] [3] [4] [5] . For instance, both estrogen treatment [3, 6, 7] and pretreatment [7] [8] [9] [10] [11] have been effective in decreasing neurological damage caused by middle cerebral artery occlusion. Epidemiological evidence further supports the role of estrogen replacement therapy in reducing the incidence of Alzheimer disease in postmenopausal women [3, 12] . Estrogen has also been shown to significantly delay the onset of kainic acid-induced clonic seizures and protect against seizure-related mortality in rats [13] . Moreover, Roof and Hall [14] showed that estrogen improved survival after traumatic brain injury (TBI) in both male and ovariectomized female rats.
It has been suggested that progesterone also has neuroprotective properties in both ischemic stroke [8] and TBI in rats [14] [15] [16] [17] [18] . In each of the above-mentioned studies, progesterone treatment was initiated between 1 h before and 24 h after TBI; three of the studies used brain edema formation at 24-48 h after injury for measurement of neuroprotection. Progesterone was effective in decreasing edema in the brain of both male and female rats [15, 16] . Furthermore, Roof et al. [18] showed that progesterone treatment 1 h after TBI facilitated cognitive recovery on a Morris water maze spatial navigation task in male rats. Progesterone treatment was further shown to lessen neuronal degeneration 21 days after injury in the medial dorsal thalamic nucleus [18] .
The incidence of ischemic stroke is 45% lower in premenopausal women than age-adjusted men [14, 19, 20] . No difference exists in the incidence of hemorrhagic stroke between the two sexes [19, 20] . Women who underwent either unilateral or bilateral oophorectomy before the onset of menopause had an increased risk of cognitive impairment or dementia compared with control women [12] . Both survival rate and functional outcome have been shown to be higher in human women following TBI [17, 21] .
Although estrogen and progesterone are well-described neuroprotective agents, the exact mechanism of estrogeninduced neuroprotection has yet to be determined. Several theories have been suggested for the mechanism of estrogen's and progesterone's neuroprotective effects. There is a large body of evidence that estrogen may mediate its neuroprotection via excitatory neurotransmitter systems, specifically, glutamate receptors [22] and glutamate transporters [23] .
It has been well established that excessive concentrations of L-glutamate (glutamate), particularly in the brain extracellular fluid and cerebrospinal fluid (CSF), have been associated with several neurodegenerative conditions resulting from acute events, including TBI, stroke, and bacterial meningitis [24] [25] [26] [27] [28] . An abnormally high glutamate concentration in brain fluids following TBI has further been correlated with a poor neurological outcome [24, 29, 30] . Increased glutamate levels can also develop chronically in certain disease states, including glaucoma, amyotrophic lateral sclerosis, and HIV dementia [31] [32] [33] . Because excess glutamate levels in brain fluids exert neurotoxic properties, a great deal of effort has been made in recent years to better understand of how the brain protects itself from excess glutamate, as well as the mechanisms by which drugs could provide neuroprotection.
Natural neuroprotection in the brain is credited mainly to the presence of members of a large family of Na þ -dependent glutamate transporters, both in nerve terminals and astrocytes. These transporters bind and take up glutamate, ensuring that the elevated concentrations of glutamate transiently present after synaptic or astrocytic release [34] are quickly decreased to concentrations at which glutamate exerts neither overtly excitatory nor excitotoxic effects [35] .
The glutamate transporters present on the antiluminal side of the brain capillary endothelial cells are partially responsible for the elimination of glutamate from the brain into the blood [36, 37] . Using injections of radiolabeled glutamate into the cisterna magna, it has been shown that a brain-to-blood glutamate efflux exists and can be accelerated by creating a larger glutamate concentration gradient between the CSF and blood plasma [38] . A decrease in blood glutamate levels and an increase in the driving force for the brain-to-blood glutamate efflux have been achieved by exploiting the glutamatescavenging properties of the blood resident enzymes glutamate-pyruvate transaminase (GPT) and glutamate-oxaloacetate transaminase (GOT) [38] . These enzymes transform glutamate into 2-ketoglutarate in the presence of the respective glutamate cosubstrates pyruvate and oxaloacetate [38] . Using brain microdialysis, the reduction of glutamate levels in the plasma with the glutamate scavenger oxaloacetate has been shown to decrease glutamate concentrations in the brain's extracellular fluid [37] . Moreover, the artificial increase in the glutamate concentration in plasma increased glutamate in the brain's extracellular fluids [37] . Stover and Kempski [39] further showed a correlation between plasma and CSF glutamate levels in neurosurgical patients. The effectiveness of the blood glutamate scavengers oxaloacetate and pyruvate in the treatment of TBI was demonstrated on a rat model of TBI [40] [41] [42] . Both oxaloacetate and pyruvate were effective in decreasing blood glutamate levels and in improving the neurological outcome after TBI.
Glutamate's harmful effects on bone resorption in patients with early rheumatoid arthritis have been shown to be inversely related to levels of estrogen [43] . Furthermore, a previous study showed that injecting estrogen into male rats reduced blood glutamate levels. Male rats injected with Premarin (a mixture of different estrogens) had a significant and long-lasting decrease in blood glutamate concentrations [44] .
It has been suggested that estrogen and progesterone may mediate their neuroprotective properties via a glutamate-related mechanism [7, 14, [45] [46] [47] [48] . Estrogen has been shown to enhance the expression of the astrocyte glutamate transporters glutamate/aspartate transporter (GLAST) and glutamate transporter 1 (GLT), which could provide a key neuroprotective mechanism by reducing extracellular glutamate levels [45, 46] . If estrogen is capable of enhancing the expression of glutamate transporters in astrocytes, it may also increase the number of glutamate transporters on the antiluminal side of the capillary endothelium, and as such promote the transport of excess glutamate from the brain to the blood [36, 49] . Thus, estrogen might facilitate the removal of excess glutamate from the brain into the blood.
Estrogen has been shown to attenuate glutamatergicreceptor activation [7] . Studies have shown that the size of a glutamate-induced lesion was significantly reduced in rats given pretreatment with 17-beta-estradiol prior to local glutamate application [47] .
Like estrogen, progesterone's neuroprotective effects may be mediated via several mechanisms [48] . The effects of progesterone on neurotrophin expression may be mediated by transcriptional activation. Alternatively, progesterone may act through novel receptor systems (membrane progesterone receptor or GABA receptor) in order to regulate cellular events that provide neuroprotection. For example, metabolites of progesterone, such as allopregnanolone, can bind to a site within the GABA receptor complex, and subsequently potentiate the effect of GABA on its receptor. This activation of the GABA receptor, in turn, has been shown to modulate cell survival, particularly in models of excitotoxicity [14, 48] . Progesterone may also be protective through its ability to elicit the activation of specific signaling pathways relevant to neuroprotection. For example, progesterone has been found to increase the expression of antiapoptotic proteins, such as Bcl-2 [50] . Additionally, progesterone has been described as having antioxidant effects [14, 16] , which may also contribute to neuronal survival following injury. Finally, progesterone has been shown to attenuate responsiveness to excitatory amino acids as well as protect neurons from glutamate toxicity in vitro [14] .
The purpose of this study was to investigate the effects on blood glutamate levels of plasma estrogen and progesterone levels during the female menstrual cycle. Fluctuations of plasma estrogen and progesterone levels during the average 28-day menstrual cycle are predictable [51] [52] [53] [54] [55] [56] [57] .
We expected that blood glutamate levels would reach a maximal value during the start of the menstrual cycle, coinciding with minimal plasma levels of estrogen and progesterone. It was further expected that gradual decreases in blood glutamate levels would coincide with elevating plasma estrogen and progesterone levels.
MATERIALS AND METHODS
This study was conducted at Soroka University Medical Centre, Beer Sheva, Israel, and was approved by the Institutional Review Board of Soroka University Medical Centre. Written informed consent was obtained from each participant. A single blood sample was taken from 31 healthy men between the ages of 18 and 49 yr. These values served as controls because hormone levels do not normally fluctuate in men [58] . A total of 45 healthy menstruating women ages 18-45 yr participated in the study. The length of each menstrual cycle ranged between 26 and 32 days. Women taking oral contraceptives and women with irregular menstrual cycles were excluded from participating. A 10-ml venous blood sample was collected four times from each participant.
The first female blood sample was collected during the first day of the participant's menstrual cycle, when expected plasma levels of estrogen and progesterone are lowest [51, 57] . The second blood sample was taken on Day 7, when levels of estrogen are moderately elevated compared with baseline plasma levels, and progesterone levels are relatively low [51, 57] . We calculated the day of ovulation by subtracting 14 days from the expected date of the next menstruation. The third blood sample was collected 2 days before the date of ovulation, when plasma estrogen levels are expected to be at their peak values [51, 57] . At this time, blood progesterone is expected to be moderately elevated [51, 57] . The last blood sample was obtained 9 days following the third sample, which was approximately 7 days before the start of the next expected menstrual cycle. This last blood sample reflected elevated plasma levels of estrogen and maximal plasma levels of progesterone [57] . As such, blood samples were drawn on Days 1, 7, 12, and 21 of the female menstrual cycle. 582 ZLOTNIK ET AL.
The collected blood was sent for determination of glutamate, estrogen, progesterone, glucose, GOT, and GPT. Blood glucose level was determined immediately after collecting the blood sample with a ''glucocheck'' blood glucose monitoring device. The GOT and GPT levels were determined in the biochemical laboratory of Soroka Medical Center via the fluorescent method.
Determination of Blood Glutamate Levels
Whole blood (200-ll aliquot) was deproteinized by adding an equal volume of ice-cold 1 M perchloric acid (PCA) and then centrifuging at 10 000 3 g for 10 min at 48C. The pellet was discarded and the supernatant collected, adjusted to a pH of 7.2 with K 2 CO 3 (2 M), and, if needed, stored at À808C for later analysis. Glutamate concentrations were measured using the fluorometric method of Graham and Aprison [59] . A 20-ll aliquot from the PCA supernatant was added to 480 ll of a 0.3 M glycine, 0.25 M hydrazine hydrate buffer adjusted to pH 8.6 with 1N H 2 SO 4 , and 15 U of glutamate dehydrogenase in 0.2 mM NAD. After incubation for 30-45 min at room temperature, the fluorescence was measured at 460 nm with excitation at 350 nm. A glutamate standard curve was established, with concentrations ranging from 0 to 6 lM. All determinations were done at least in duplicate.
Determination of Plasma Estrogen and Progesterone Levels
For the determination of estrogen and progesterone levels in plasma, collected blood was centrifuged, and the serum was stored in a freezer at À808C until analysis. Measurements were performed in the endocrinology lab of Soroka Medical Center using an ADVIA Centaur Estradiol/Progesterone Assay (Bayer). The assay principle was based on competitive immunoassay, allowing for the production of highly specific antibodies to be measured via direct chemiluminescent technology.
Statistical Analysis
Levels of glutamate, glucose, GOT, and GPT were compared between male and female groups during the start of menstruation using a two-tailed t-test for equality of means. For comparisons of glutamate, glucose, estrogen, progesterone, GOT, and GPT levels of women across days of the menstrual cycle, a repeated-measures ANOVA was used. A paired t-test was conducted to compare samples of blood glutamate, estrogen, and progesterone levels in women. Differences in data were considered significant when P , 0.05. Data are presented as means 6 SEM.
RESULTS
Blood glucose, plasma GOT, and plasma GPT values in men and women are displayed in Table 1 . There were no significant differences between men and women (measured at the start of menstruation) with respect to blood glucose concentration, nor was there a difference within the female group during the menstrual cycle. The GOT concentrations did not change across days within the female group. Concentrations of GOT were significantly higher in men than in women during the entire cycle (P , 0.05). The GPT concentrations also remained constant within the female group throughout the menstrual cycle. Concentrations of GPT were significantly higher in men than in women during the entire cycle (P , 0.001).
Blood glutamate concentrations were significantly higher in men than in women at the start of menstruation (211 6 17 vs. 169 6 6 lM/L; P , 0.05). There was a difference in glutamate levels in women across days (P , 0.001). Blood glutamate levels in women decreased significantly by the second sample collection (169 6 6 vs. 140 6 7 lM/L; P , 0.01). The third blood sample's glutamate further decreased compared with either the first or the second blood sample, to 93 6 6 lM/L (P , 0.001). Glutamate levels in the last blood sample were measured at 106 6 4 lM/L, which was significantly higher than the third sample (P , 0.05) and significantly lower than the first or the second blood sample (P , 0.001).
There was a difference in plasma estrogen and progesterone levels in women across days (P , 0.001). Plasma estrogen levels were significantly elevated by the second sample collection (52 6 3 vs. 61 6 4 pg/ml; P , 0.05). Estrogen levels continued to rise, reaching their peak value of 386 6 24 pg/ml during the third sample collection, which was significantly higher than the first sample collection (P , 0.001). Estrogen levels were also elevated during the fourth sample collection compared with the first sample (254 6 23 pg/ml; P , 0.001). Plasma progesterone levels were significantly increased by the third sample collection (0.71 6 0.23 vs. 3 6 0.09 ng/ml; P , 0.001). Progesterone levels increased dramatically, reaching their peak value of 12 6 3 pg/ml during the fourth sample collection, which was significantly higher than the first sample collection (P , 0.001). Measured female plasma levels of estrogen, progesterone, and glutamate throughout the menstrual cycle are presented in Figure 1 .
DISCUSSION
The principal finding in the current study was that blood glutamate levels are inversely correlated with levels of plasma estrogen and progesterone. Our previous work with rats has shown that low blood glutamate levels strongly correlate with the brain's extracellular glutamate concentrations [37, 38] . Additionally, it has been demonstrated that lower blood glutamate concentrations were associated with a better neurological outcome after TBI [40] [41] [42] . Therefore, potential factors that reduce blood glutamate concentration may lead to a reduction of brain glutamate concentrations and provide neuroprotection.
We postulated that the neuroprotective effects of the female hormones estrogen and progesterone may be mediated via their blood glutamate-reducing properties. The present study suggests an inverse correlation between plasma estrogen and progesterone concentrations and blood glutamate levels. The data are presented as mean 6 SEM. b There were no differences between men and women with respect to blood glucose concentrations. Blood glucose remained constant in women throughout the menstrual cycle. c Males were measured to have higher levels of GOT (*P , 0.05) than women irrespective of day within the menstrual cycle. d Males were measured to have higher levels of GPT (**P , 0.001) than women irrespective of day within the menstrual cycle; levels of GPT were almost twice as high in men.
Men have very low levels of estrogen and progesterone, yet almost twice the amount of glutamate was measured in their blood compared with women. Exploring the evolution of blood glutamate levels throughout the menstrual cycle further supports an inverse correlation between estrogen and progesterone levels and blood glutamate levels.
Fluctuations of plasma estrogen and progesterone levels during the menstrual cycle were consistent with values previously described in the literature [51] [52] [53] [54] [55] [56] [57] . The first collected blood samples, reflecting a period when levels of both estrogen and progesterone are lowest, were also found to have the highest level of glutamate concentrations in women. As plasma estrogen levels began to gradually increase, a moderate decrease of blood glutamate (by approximately 17%) was noted, despite persistently low progesterone levels. The third and fourth blood samples, which represented the period where the highest levels of estrogen and progesterone are seen, blood glutamate levels dropped to almost half the initial values seen at the start of the cycle.
Surprisingly, there were slightly lower blood glutamate levels in the third blood sample than in the last blood sample. Although levels of estrogen reached their peak value during the period when the third blood sample was drawn, estrogen levels remained relatively high during the fourth sample period, when progesterone levels were maximal. Assuming that both estrogen and progesterone play an equal role in maintaining low blood glutamate levels, it is expected that blood glutamate levels should be lowest in the last sample. The discrepancy may suggest that estrogen plays a more significant role in the regulation of blood glutamate. However, it has been shown previously that neuroprotection by progesterone has a bellshaped dose-response curve, with doses of 4-18 mg/kg being most effective and a disappearance of the effect observed at higher and lower concentrations [17] . Therefore, if progesterone-induced neuroprotection is the result of a glutamatereducing effect, the same bell-shaped curve would suggest a more pronounced effect at lower progesterone levels, as seen during the third sample period in this study.
Levels of GOT and GPT did not change throughout the female menstrual cycle. Therefore, the reduction of blood glutamate in the current study cannot be explained by the conversion of glutamate to its inactive form 2-ketoglutarate by GOT and GPT in the presence of coenzymes oxaloacetate and pyruvate, respectively.
Because of their blood glutamate scavenging, higher levels of GOT and GPT in the female population can be expected in comparison with the male population in order to sustain lower levels of glutamate in blood. Thus, it would seem contradictory that women were found to have both lower blood glutamate levels and lower levels of GOT and GPT. A possible explanation for this phenomenon may be that estrogen or progesterone genetically determines lower glutamate levels in women by a GOT/GPT scavenging-independent mechanism. In this situation, fewer enzymes (GOT and GPT) would be necessary to convert the lower amounts of glutamate into 2-ketoglutarate. Another speculative explanation may be that estrogen and progesterone determine higher concentrations of oxaloacetate and pyruvate in plasma, serving as coenzymes for GOT and GPT, respectively. In this situation, as expected from the Michaelis-Menten enzyme rate equation, lower levels of GOT and GPT would be necessary to convert the same amount of glutamate into 2-ketoglutarate, sustaining lower concentrations of glutamate in women's blood [41, 42] . The exact mechanisms by which estrogen and progesterone mediate their blood glutamate-reducing effect are not clear, and additional studies are warranted.
Estrogen has been shown to attenuate glutamatergicreceptor activation [7] . In rats, pretreatment with intravenous 17-beta-estradiol before the local application of glutamate was shown to significantly reduce the size of the glutamate-induced lesion [47] . Progesterone also has been shown to attenuate responsiveness to excitatory amino acids and to protect neurons from glutamate toxicity in vitro [14] . Exposing the hypothalamus in vitro to glutamate has been shown to increase the synthesis and production of gonadotropin-releasing hormone (GnRH) [60] , as well as estrogen, directly from cholesterol via FIG. 1. Measured blood estrogen, progesterone, and glutamate levels in women throughout the menstrual cycle. The blood samples were drawn on Days 1, 7, 12, and 21 of the menstrual cycle. The bars indicate the SEM. In comparison with measured plasma levels on Day 1, there was a significant increase in estrogen levels on Days 7 (*P , 0.05), 12, and 21 (***P , 0.001), and an increase in progesterone levels on Days 12 and 21 (***P , 0.001). There was a significant decrease in female blood glutamate levels on Days 7, 12, and 21 in comparison with blood glutamate levels on Day 1 (***P , 0.001). Furthermore, there was a significant decrease in blood glutamate levels on Days 12 and 21 in comparison with blood glutamate levels on Day 7 (#P , 0.001). The blood sample on Day 21 was significantly higher than the sample collected on Day 12 (^P , 0.05). 584 hypothalamic neurons [45] . We are suggesting that estrogen plays a significant role in the autoregulation of blood and brain glutamate levels. An increase in glutamate would increase the secretion of GnRH, which in turn would stimulate the secretion of estrogen. This estrogen then would downregulate (decrease) elevated glutamate levels in the plasma, thus decreasing glutamate levels in the brain.
To date, there is very little in the literature on the influence of sex differences on glutamate levels. It has been described by Stover and Kempski [39] that following isoflurane administration in neurosurgical procedures, glutamate concentrations are more prominently elevated in male patients than in female patients. Baseline levels of glutamate were also found to be lower in female patients [39] . Although this observation was not addressed further in the paper, this finding may support the theory that women have lower blood glutamate levels, promoting neuroprotection.
A major limitation of this study was that the design did not allow the distinction between the blood glutamate-reducing effects of estrogen and progesterone. Therefore, future experiments on animal subjects are warranted. It would have further been of interest to investigate the effects of estrogen and progesterone on other amino acids; however, we focused on glutamate levels in particular because of their neurotoxic effects, and thus measuring other amino acids was felt to be out of the scope of this study. In addition, the current study does not describe the exact mechanism by which glutamate is reduced, necessitating additional investigations in this area as well.
In summary, the study provides some insight into the role of estrogen and progesterone in the reduction of blood glutamate concentrations. This work may help lead to the discovery of factors that can prevent secondary brain injury from glutamateinduced neurotoxicity, and offer new therapeutic strategies for the treatment of TBI, stroke, and chronic neurodegenerative disorders.
